Glancy Prongay Wolke & Rotter LLP reminds investors that August 10, 2026 is the deadline to seek lead plaintiff status in a securities fraud class action against ADMA Biologics, Inc. The lawsuit covers purchasers of ADMA securities between August 9, 2024 and March 25, 2026. The action follows a March 24, 2026 Culper Research report alleging channel stuffing, an undisclosed related party distributor, and that real 2025 growth was negative 3% versus a reported 20% increase. ADMA's stock fell $3.96, or 29.1%, over two trading days to close at $9.63 per share on March 25, 2026. The complaint claims defendants made false and misleading statements and failed to disclose material adverse facts about the company's business, operations, and prospects.
ADMA Biologics IncSecurities fraud class action lawsuit alleging false statements and channel stuffing, causing 29% stock drop.